FDA Adds Vision Loss Warning to Ozempic, Zepbound

Share this post
4 min read

Last updated November 15, 2026

The FDA will add a warning about a rare eye condition to Ozempic, Wegovy, Zepbound and other GLP-1 drugs. Here is how rare it is and what signs to watch.

Key Points

  • The Food and Drug Administration (FDA) announced the warning on November 9.
  • It covers a rare condition that cuts blood flow to the optic nerve.
  • In trials, it affected about 6 in 100,000 people taking a GLP-1 drug for a year or more.
  • Call a doctor right away for blurry vision, blind spots or color changes.

What the FDA Announced

All GLP-1 drugs will get a new label warning about an eye condition called NAION. That stands for non-arteritic anterior ischemic optic neuropathy, CBS News reported.

The drugs include Ozempic and Wegovy from Novo Nordisk, and Zepbound and Mounjaro from Eli Lilly.

The FDA review began after a 2024 medical paper linked the condition to some people taking semaglutide.

Good to know. Vision loss from NAION in one eye does not predict what happens in the other eye, an eye expert told CBS News.

The Numbers So Far

FactFigureSource
Warning announcedNovember 9, 2026CBS News
Trials reviewedMore than 125CBS News
NAION rate on GLP-1 drugsAbout 6 per 100,000CBS News
Rate on placebo or other drugsUnder 4 per 100,000CBS News
Drugs namedOzempic, Wegovy, Zepbound, MounjaroU.S. News
6 in 100,000Rate of NAION among people taking a GLP-1 drug for a year or more in trials, per CBS News.

What Is NAION?

NAION happens when blood flow to the optic nerve drops. It can cause serious vision loss that is sometimes permanent.

People who do not take GLP-1 drugs can get it too. It affects about 2 to 10 in 100,000 adults over 50. That estimate is from the American Academy of Ophthalmology, as cited by CBS News.

Claim vs Fact

Claim you may hearWhat the record shows
GLP-1 drugs make many people go blindNAION is rare, about 6 in 100,000 users in trials
The FDA banned OzempicThe FDA added a label warning, it did not pull the drugs
Drug makers agree it causes NAIONNovo Nordisk says the data do not prove it

Does this warning change how you feel about GLP-1 drugs?

  • Yes, I am more worried
  • No, the risk seems small
  • I will ask my doctor
  • Not sure

Free updates

Join the Digieh list

Be the first to know when our weekly brief launches.

No spam. Unsubscribe anytime. Read our Privacy Policy.

What the Drug Makers Say

Novo Nordisk said the data do not establish a cause-and-effect relationship. Eli Lilly said it is carefully evaluating the update, per CBS News.

The news was also reported by Reuters via U.S. News.

Why It Matters

Millions of people take GLP-1 drugs for diabetes or weight loss. The warning helps patients and doctors spot eye problems early.

New to these drugs? Read our guide to GLP-1 medicines explained. Screen time can also strain eyes, so see our tips on how to reduce eye strain.

When to Get Help

Contact a doctor right away if you take a GLP-1 drug and notice any of these signs, the FDA says.

  • Blurred vision
  • Blind spots
  • Colors that look faded or wrong
  • Any sudden change in vision

Do not stop your medicine on your own. Talk with your doctor first. This article is for information only and is not medical advice.

  • Know the warning signs of NAION
  • Report vision changes to your doctor right away
  • Keep up with regular eye exams
  • Do not stop medicine without medical advice
Try this today. If you take a GLP-1 drug, book an eye exam if you have not had one this year.

What did the FDA do on November 9?

  1. Banned GLP-1 drugs
  2. Recalled Ozempic
  3. Ordered a new eye risk warning on labels

The FDA ordered a label warning about NAION for all GLP-1 drugs.

Frequently Asked Questions

Does Ozempic cause vision loss?

The FDA added a warning about NAION, a rare eye condition. Novo Nordisk says the data do not prove the drug causes it.

How rare is NAION with GLP-1 drugs?

An FDA review of trials found about 6 cases per 100,000 patients. Those patients took a GLP-1 drug for at least a year.

Should I stop taking my GLP-1 medicine?

Do not stop on your own. Talk with your doctor, and report any vision changes right away.

Found this useful?

Editor’s Note

This story is accurate as of November 15, 2026. It is based on the FDA announcement as reported by CBS News and Reuters. It is not medical advice.

Spot an error in this article? Please contact us at support@digieh.com or read our Corrections Policy.

Keep exploring

Your next read is waiting

Share this post
Avatar photo

Syed Wasif Raza

Syed Wasif Raza is the founder and editor of Digieh. He writes about health, food, lifestyle, news and sports in plain, easy English. Every guide he publishes is checked against official sources such as government and health agency pages. Connect with him on LinkedIn.

Articles: 640

Leave a Reply

Your email address will not be published. Required fields are marked *